We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Quad‐class exposed/refractory myeloma is associated with short survival.
- Authors
Piron, Bénédicte; Costes‐Tertrais, Domitille; Gastinne, Thomas; Fourmont, Aude Marie; Dubruille, Viviane; Blin, Nicolas; Moreau, Philippe; Touzeau, Cyrille; Tessoulin, Benoit
- Abstract
Summary: Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti‐CD38 monoclonal antibody and therapies targeting B‐cell maturation antigen (BCMA) (Quad‐class exposed [QCE]). In this retrospective single‐centre study, we determined progression‐free survival (PFS) and overall survival (OS) from anti‐BCMA failure in 45 QCE patients. Seven (16%) patients received antibody‐drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR‐T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4–12.5) and OS 6.3 months (95% CI = 3.9–14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
- Subjects
BISPECIFIC antibodies; MULTIPLE myeloma; ANTIBODY-drug conjugates; PROGRESSION-free survival; PROTEASOME inhibitors
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 1, p186
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19148